Tuberculosis Diagnostics Market Analysis 2026

Market Dynamics:

Key Drivers:

• Initiatives taken by governments for the prevention of disease leads to surge the demand for Tuberculosis Diagnostics.

For the development of the country and to reduce the number of patients suffering from tuberculosis, governments have taken initiatives like policy implementation, increasing awareness, and providing necessary factors. Several people opt for treatment from the private sector but there remains a group of people who are not able to afford such expensive treatments. Here the government has to step in to help provide quality health services that are also accessible for all. It not only protects the workers financially but also ensures that they are protected from unfair treatment and have the right to good health.  For Instance, The "Differentiated Care of TB Patients" initiative is being carried out by World Health Partners (WHP) and John Snow, Inc. The initiative is being implemented in Uttar Pradesh's high-notification public health facilities in the districts of Barabanki, Unnao, Kanpur, and Lucknow. To lower morbidity and avoidable death among TB patients, the project will design and implement a complete package of diagnostic and referral services across multiple healthcare facilities.(Source:https://worldhealthpartners.org/tifa.php?page=project) The treatment of tuberculosis consists of blood tests, Skin tests, X-rays, Sputum tests combination of medicines for antibacterial drugs which have to be taken for 6-12 months. This treatment can be done by people who can afford to do the above-mentioned tests and take the medicines. For example, from the standpoints of the health system and society, the unit cost of a tuberculosis diagnosis per individual was USD 27.22 and USD 70.16, respectively.

(Source:http://system and society, the unit cost of a tuberculosis diagnosis per individual was USD 27.22 and USD 70.16) ,So to solve the problem of funding, Government initiatives help them in terms of financing. For Instance, For India's "TB Mukt Bharat" objective to be successful, funding for healthcare is essential. A robustly financially supported healthcare system will protect the interests of marginalized and vulnerable groups, including women, children, and rural residents. Therefore, due to all reasons, Government initiatives play a role in the improvement of health care and facilitating the people for their betterment.

(Source:https://www.hindustantimes.com/ht-insight/public-health/realise-tb-mukt-bharat-by-financing-india-s-health-care-system-101679638150491.html)

• The increase in Tuberculosis and MDR-TB Cases globally boosts the market for Tuberculosis Diagnostics

One of the main drivers for this market is the crucial increase in cases of tuberculosis. According to WHO, after COVID-19, tuberculosis is the second most common infectious killer globally, surpassing HIV and AIDS. 10.6 million cases of tuberculosis (TB) are there globally in 2022. The reasons for this disease if high blood sugar levels, malnourished, or a weak immune system. Low-income and middle-income countries have over 80% of tuberculosis cases and deaths and in 2021, 30 countries had high tuberculosis rates and 87.0% of new cases. Thus, there is a need globally for the treatment of this disease. A bacterium that is driven to a minimum of isoniazid and rifampin, the two most effective TB medications, is the source of multidrug-resistant tuberculosis (MDR TB)

(Source:https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=Worldwide%2C%20TB%20is%20the%20second,all%20countries%20and%20age%20groups)All patients with tuberculosis are treated with these medications. The MDR-TB is a multi-drug resistant Tuberculosis, there is an increase in this multi-drug resistance because of ill-treatment and mismanaging the Tuberculosis treatment. Not using the drugs correctly or poor quality of drugs leads to cause in drug resistance. This can then be easily transmitted from person to person in any public area or hospital. For Instance, According to WHO’s most recent anti-TB drug resistance surveillance statistics, multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) is thought to be present in 3.5% of new cases of TB, and 18% of cases of TB that have already been treated globally. Thus, such a strong and increasing rate of cases increases the demand for the diagnostic market and growth in the upcoming years.(Source:https://www.who.int/publications/m/item/multidrug-resistant-tuberculosis-(mdr-tb)#:~:text=Download%20(579.9%20kB)-,Overview,MDR%2FRR%2DTB)

 Key Restraints:

• Technological challenges can hamper the growth of the market

Although better diagnostic technologies for tuberculosis are critically needed and becoming more so, there are a few obstacles that could hinder market expansion in the next years. For example, certain technical issues with tuberculosis diagnostics may be a significant barrier to market revenue growth. Furthermore, one of the main factors preventing the market's revenue from growing faster is the greater technical difficulty involved in creating these diagnostic technologies. The most common diagnostic test for tuberculosis, for example, is sputum smear microscopy, albeit it has drawbacks like low sensitivity. Additionally, this could lead to false positive results in other infections like people with HIV for the elderly, and children. Furthermore, it cannot be utilized to rule out tuberculosis extrapulmonary. It is anticipated that the technological complexity associated with tuberculosis diagnostics may hinder the market (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705651/#:~:text=However%2C%20sputum%20smear%20microscopy%20has,10%2C000%20organisms%2Fml%20sputum%20sample.)

What was the impact of COVID-19 on tuberculosis Diagnosis?

As the outburst of COVID-19 affected the healthcare industry causing more types of diseases. Contrarily, Tuberculosis cases reduced during the pandemic and so the diagnosis market also slowed down. According to the Central TB Division, There has been an overall decline in TB notification by 26% from January to June 2020 as compared to the previous year, due to the COVID-19 pandemic. COVID-19 reduced the rate of testing for Tuberculosis in the global market. For Instance, according to the Global Fund, the number of patients receiving treatment for drug-resistant tuberculosis fell by a startling 19% in 2020 in the countries where the Global Fund makes investments, with a further decline of 37% observed in those receiving treatment for extensively drug-resistant tuberculosis. There was a 16% decrease in the number of HIV-positive TB patients receiving both TB treatment and antiretroviral therapy.(Source:https://www.theglobalfund.org/en/news/2021/2021-09-08-global-fund-results-report-reveals-covid-19-devastating-impact-on-hiv-tb-and-malaria-programs/)Talking about the market of Diagnosis of Tuberculosis, it decreased due to a smaller number of cases. But the symptoms of COVID-19 and Tuberculosis are the same, both are infectious diseases caused by the lungs. COVID-19 is far more dangerous for the health and TB has an incubation period of long and the onset is slower.  The number of reports of TB diagnoses is one of the most accessible metrics that may be used to evaluate the effect of COVID-related interruptions on vital TB services at the international, regional, and national levels. This indicator shows how access to diagnosis and treatment is affected by both the supply and demand lockdowns and related movement restrictions, worries about the safety of visiting medical facilities during a pandemic, and the stigma associated with symptoms of tuberculosis and COVID-19 being similar. 
 

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Tuberculosis Diagnostics Market is witnessing significant growth in the near future.

In 2023, the Smear Microscopy segment accounted for noticeable share of global Tuberculosis Diagnostics Market and is projected to experience significant growth in the near future.

The Hospital segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies Abbott Laboratories, Alere Inc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions